JP2020516601A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516601A5
JP2020516601A5 JP2019554737A JP2019554737A JP2020516601A5 JP 2020516601 A5 JP2020516601 A5 JP 2020516601A5 JP 2019554737 A JP2019554737 A JP 2019554737A JP 2019554737 A JP2019554737 A JP 2019554737A JP 2020516601 A5 JP2020516601 A5 JP 2020516601A5
Authority
JP
Japan
Prior art keywords
antigen
tumor
protein
arenavirus
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516601A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/058900 external-priority patent/WO2018185307A1/en
Publication of JP2020516601A publication Critical patent/JP2020516601A/ja
Publication of JP2020516601A5 publication Critical patent/JP2020516601A5/ja
Pending legal-status Critical Current

Links

JP2019554737A 2017-04-07 2018-04-06 固形腫瘍を治療するためのアレナウイルス粒子 Pending JP2020516601A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483067P 2017-04-07 2017-04-07
US62/483,067 2017-04-07
PCT/EP2018/058900 WO2018185307A1 (en) 2017-04-07 2018-04-06 Arenavirus particles to treat solid tumors

Publications (2)

Publication Number Publication Date
JP2020516601A JP2020516601A (ja) 2020-06-11
JP2020516601A5 true JP2020516601A5 (enExample) 2021-05-20

Family

ID=62025795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554737A Pending JP2020516601A (ja) 2017-04-07 2018-04-06 固形腫瘍を治療するためのアレナウイルス粒子

Country Status (7)

Country Link
US (1) US20200113995A1 (enExample)
EP (1) EP3606549A1 (enExample)
JP (1) JP2020516601A (enExample)
CN (1) CN110719788A (enExample)
AU (1) AU2018247958A1 (enExample)
CA (1) CA3058539A1 (enExample)
WO (1) WO2018185307A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2604695T1 (sl) 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Cmvワクチン
SI3218504T1 (sl) 2014-11-13 2020-11-30 Universite De Geneve Tri-segmentirani arenavirusi kot vakcinski vektorji
AU2016274655B2 (en) * 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
CA3003557A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
DK3373959T3 (da) 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
BR112022024404A2 (pt) * 2020-05-29 2023-02-07 Hookipa Biotech Gmbh Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
US20240229073A1 (en) * 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
CA3236106A1 (en) 2021-11-08 2023-05-11 Henning Lauterbach Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2023174998A1 (en) * 2022-03-16 2023-09-21 Boehringer Ingelheim International Gmbh Tumor antigens, compounds comprising the tumor antigens kras, tpx2 or aurka and uses thereof
CN115192709B (zh) * 2022-05-12 2023-07-21 黄淮学院 O-GlcNAc糖基转移酶抑制剂在制备抑制精子发生的药物中的用途
CN116218681B (zh) * 2022-08-02 2025-11-11 汕头大学 三角褐指藻钙网蛋白基因过表达突变株的构建方法
WO2025101837A1 (en) * 2023-11-10 2025-05-15 Eccletech Llc Biological devices and methods of using the same for detection of different types of cancer
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1553966B1 (en) * 2002-10-03 2012-08-01 Wyeth Holdings Corporation Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
SI2604695T1 (sl) * 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
EP3110443A4 (en) * 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
SI3218504T1 (sl) * 2014-11-13 2020-11-30 Universite De Geneve Tri-segmentirani arenavirusi kot vakcinski vektorji
DE102015207036A1 (de) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
AU2016274655B2 (en) * 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
DK3373959T3 (da) * 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
IL262963B2 (en) * 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
US20200206334A1 (en) * 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Similar Documents

Publication Publication Date Title
JP2020516601A5 (enExample)
JP2023500928A5 (enExample)
JP2018533604A5 (enExample)
JP2019533690A5 (enExample)
HRP20221167T1 (hr) Čestice arenavirusa kao cjepiva protiv raka
JP2023029898A5 (enExample)
Rühl et al. Vaccination against the Epstein–Barr virus
Flingai et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants
JP2010533649A5 (enExample)
JP7783631B2 (ja) ベクターとしてのアレナウイルス
JP6219849B2 (ja) 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
WO2018185307A1 (en) Arenavirus particles to treat solid tumors
BR112020003007A2 (pt) modificação de células t
US20190000943A1 (en) Aav6 vectors for immunotherapy
KR20260012231A (ko) 백신접종용 항원-특이적 생리학적 수지상 세포
Cubillos-Zapata et al. Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo
Wang et al. Development of a novel PCV2 and PCV3 vaccine using virus-like vesicles incorporating Venezuelan equine encephalomyelitis virus-containing vesicular stomatitis virus glycoprotein
Sherritt et al. Effect of pre‐existing cytotoxic T lymphocytes on therapeutic vaccines
WO2011056993A1 (en) Compositions and methods for treating cancer with attenuated oncolytic viruses
US20140286978A1 (en) Cytotoxic t lymphocyte inducer
US20210369635A1 (en) Novel methods of vaccination using icosahedral phage
US20240245765A1 (en) Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines
Rossiter Attempts to protect rabbits against challenge with virulent, cell-associated, malignant catarrhal fever virus
Orchard et al. Interleukin-2 secretion by transduced and unselected BDL-2 lymphoma results in increased survival in mice with previously established disseminated disease
Böhm et al. DNA-Based Vaccination Primes Tumor-Rejecting T-Cell Responses